Amendments to the Claims

1-5. (cancelled)

6. (Currently Amended) A method of inhibiting membrane fusion between HIV and a target cell that expresses CCR5 or between an HIV-infected cell and a CD4 positive uninfected cell that expresses CCR5, comprising contacting the target or CD4 positive cell with a fusion-inhibiting effective amount of a CCR5 binding or blocking agent, wherein the binding or blocking agent comprises a chemokine, an anti-CC5 antibody or epitope binding fragment thereof, or a peptide corresponding to an extracellular loop of CCR5.

7. (Previously Presented) The method of claim 6, wherein the agent is an anti-CCR5 antibody or epitope binding fragment thereof.

8. (Previously Presented) The method of claim 7, wherein the antibody is a monoclonal antibody or a polyclonal antibody.

9. (Previously Presented) The method of claim 6, wherein the contacting is by *in vivo* administration to a subject.

10. (Previously Presented) The method of claim 7, wherein the anti-CCR5 antibody is administered by intravenous, intra-muscular or subcutaneous injections.

11. (Currently Amended) The method of claim [[9]]10, wherein the anti-CCR5 antibody is administered within a dose range of 0.1 μg/kg to 100 mg/kg.

12. (Previously Presented) The method of claim 10, wherein the antibody is formulated in a pharmaceutically acceptable carrier.

13. – 17. (Canceled)

18. (Currently Amended) A method of treating a subject having an HIV-related disorder associated with ~~expression~~ HIV-1 fusion coreceptor activity of CCR5 comprising administering to an HIV infected or susceptible cell of the subject, an agent that suppresses the HIV-1 fusion coreceptor activity of CCR5.

19. (Previously Presented) The method of claim 18, wherein the agent is an anti-CCR5 antibody.

20. (Canceled)

21. (Currently Amended) The method of claim 18, wherein the agent is introduced ~~in~~to the cell using a carrier.

22. (Currently Amended) The method of claim [[18]]21, wherein the carrier is a vector.

23. (Previously Presented) The method of claim 18, wherein the administering is *ex vivo*.

24. (Previously Presented) The method of claim 18, wherein the administering is *in vivo*.

25. (New) The method of claim 6, wherein the chemokine comprises RANTES, MIP-1α, or MIP1-β.

26. (New) The method of claim 6, wherein the extracellular loop of CCR5 comprises SEQ ID NO: 5, 6 or 7.

27. (New) The method of claim 6, wherein the extracellular loop of CCR5 consists of SEQ ID NO: 5, 6 or 7